Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹5,687 Cr
Revenue (TTM)
₹7 Cr
Net Profit (TTM)
₹-161 Cr
ROE
-32.6 %
ROCE
-32.8 %
P/E Ratio
--
P/B Ratio
51.7
Industry P/E
38.71
EV/EBITDA
-36.5
Div. Yield
0 %
Debt to Equity
0
Book Value
₹5
EPS
₹-7.4
Face value
1
Shares outstanding
218,073,717
CFO
₹-252.69 Cr
EBITDA
₹9.01 Cr
Net Profit
₹-144.14 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Suven Life
| 103.7 | 82.9 | 121.7 | 158.0 | 54.7 | 54.0 | 9.9 |
|
BSE Healthcare
| -2.7 | 6.6 | 11.8 | 20.4 | 25.9 | 22.3 | 11.0 |
|
BSE Small Cap
| -2.3 | 14.5 | 20.8 | 7.7 | 27.5 | 35.2 | 17.6 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Suven Life
| 55.7 | 18.0 | -16.6 | -2.4 | -70.5 | 32.3 | 10.6 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Suven Life
|
260.6 | 5,687.4 | 6.7 | -160.8 | -2,578.1 | -106.2 | -- | 51.7 |
| 473.6 | 4,323.9 | 2,387.0 | 168.1 | 9.7 | 12.7 | 25.7 | 3.2 | |
| 1,028.8 | 12,627.7 | 2,386.9 | 485.6 | 26.1 | 18.1 | 26 | 4.5 | |
| 346.1 | 3,776.2 | 150.8 | 48.8 | 42.1 | 20.7 | 77.4 | 15.2 | |
| 280.4 | 2,582.5 | 1,664.9 | -77.9 | -0.9 | -7.1 | -- | 2.5 | |
| 90.2 | 2,648.2 | 2,079.2 | 101.1 | 6.3 | 6 | 26.2 | 1.6 | |
| 66.0 | 3,617.0 | 1,811.6 | 118.0 | 8.0 | 10.4 | 30.6 | 3.1 | |
| 720.7 | 3,662.9 | 921.9 | 95.8 | 9.0 | 8 | 36.8 | 2.9 | |
| 2,245.3 | 3,718.1 | 653.4 | 183.2 | 21.2 | 20.9 | 20.3 | 7.0 | |
| 630.5 | 4,429.2 | 2,028.9 | 150.6 | 7.5 | 6.2 | 32.2 | 1.8 |
No Review & Analysis are available.
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and... internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited. Read more
Incorporated
1989
Chairman
Venkateswarlu Jasti
Managing Director
Venkateswarlu Jasti
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Suven Life Sciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Suven Life Sciences Ltd stood at ₹ 135 Cr as on 31-Mar-25
The share price of Suven Life Sciences Ltd is ₹260.57 (NSE) and ₹260.80 (BSE) as of 12-Jun-2025 15:59 IST. Suven Life Sciences Ltd has given a return of 54.7% in the last 3 years.
Suven Life Sciences Ltd has a market capitalisation of ₹ 5,687 Cr as on 12-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Suven Life Sciences Ltd is 51.71 times as on 12-Jun-2025, a 1462% premium to its peers’ median range of 3.31 times.
Since, TTM earnings of Suven Life Sciences Ltd is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Suven Life Sciences Ltd and enter the required number of quantities and click on buy to purchase the shares of Suven Life Sciences Ltd.
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities (NCEs) in central nervous system therapies. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and Ropanicant (SUVN-911), a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
The promoter of Suven Life Sciences Ltd is JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (InitscapacityassoletrusteeofJastiFamilyTrust). JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED (InitscapacityassoletrusteeofJastiFamilyTrust) owns 69.56 per cent of the total equity. The chairman of the company is Venkateswarlu Jasti , and the managing director is Venkateswarlu Jasti..
There is no promoter pledging in Suven Life Sciences Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
12,335
|
|
|
4,217
|
|
|
4,173
|
|
|
3,648
|
|
|
3,539
|
|
|
3,515
|
|
|
3,513
|
|
|
2,601
|
|
|
2,532
|
| Suven Life Sciences Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
-106.22
|
|
Operating margin(%)
|
-2578.08
|
|
Net Margin(%)
|
-915.72
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Suven Life Sciences Ltd was ₹-161 Cr.
₹13.55
(
